Jeremy Ramdial, MD
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jeremy Ramdial, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06668584 · A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid MalignanciesM.D. Anderson Cancer Center · recruiting · Myeloid Malignancies · principal investigator
- Ph1/Ph2NCT06383572 · Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesM.D. Anderson Cancer Center · recruiting · Lymphodepleting Chemotherapy, Myeloid Malignancies · principal investigator
- Ph2NCT05115630 · Off-the-shelf NK Cells + SCT for Myeloid MalignanciesM.D. Anderson Cancer Center · completed · Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- NK Cell Engineering to Target Intracellular Antigens in AMLR01CA310933 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2026 · $442,146 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in chronic myeloid leukemia.